Drug Information
| Drug General Information | |||||
|---|---|---|---|---|---|
| Drug ID |
D09OQV
|
||||
| Former ID |
DCL000889
|
||||
| Drug Name |
N-0923
|
||||
| Synonyms |
Neupro; Rotigotine; Rotigotine CDS; Rotigotine CDS Patch; Rotigotine transdermal patch; N 0437; N 0923; N 0924; SPM 962; N-0437; N-0924; Neupro (TN); Rotigotine [USAN:INN]; SPM-936; SPM-937; SPM-962; Rotigotine (USAN/INN); N 0437, (-)-isomer; (-)-(S)-5,6,7,8-Tetrahydro-6-(propyl(2-(2-thienyl)ethyl)amino)-1-naphthol; (-)-N-0437; (6S)-6-(Propyl(2-(2-thienyl)ethyl)amino)-5,6,7,8-tetrahydro-1-naphthalenol; (6S)-6-[propyl(2-thiophen-2-ylethyl)amino]-5,6,7,8-tetrahydronaphthalen-1-ol; 2-(N-n-Propyl-N-2-thienylethylamino)-5-hydroxytetralin; 6-(Propyl(2-(2-thienyl)ethyl)amino)-5,6,7,8-tetrahydro-1-naphthalenol; 6-[propyl(2-thiophen-2-ylethyl)amino]-5,6,7,8-tetrahydronaphthalen-1-ol
|
||||
| Drug Type |
Small molecular drug
|
||||
| Indication | Parkinson's disease [ICD9: 332; ICD10:G20] | Approved | [1], [2] | ||
| Company |
National Cancer Institute (NCI)
|
||||
| Structure |
|
Download2D MOL |
|||
| Formula |
C19H25NOS
|
||||
| Canonical SMILES |
CCCN(CCC1=CC=CS1)C2CCC3=C(C2)C=CC=C3O
|
||||
| InChI |
1S/C19H25NOS/c1-2-11-20(12-10-17-6-4-13-22-17)16-8-9-18-15(14-16)5-3-7-19(18)21/h3-7,13,16,21H,2,8-12,14H2,1H3/t16-/m0/s1
|
||||
| InChIKey |
KFQYTPMOWPVWEJ-INIZCTEOSA-N
|
||||
| CAS Number |
CAS 99755-59-6
|
||||
| PubChem Compound ID | |||||
| PubChem Substance ID |
12014593, 14752454, 14752455, 17186146, 43116758, 47207429, 50065448, 50113269, 57313947, 80319505, 92720050, 93308798, 103403788, 104016053, 104317509, 126620376, 126649059, 126652305, 126668282, 128375597, 131331909, 134222775, 134339011, 134339342, 134339911, 134340448, 135016328, 135650929, 137239502, 142666076, 143493345, 144206180, 152240256, 152258902, 160647749, 162011478, 163122815, 170465204, 171578547, 174531819, 175268915, 179151436, 185974303, 187072933, 196106681, 198987592, 204360677, 206711592, 218903400, 223382851
|
||||
| SuperDrug ATC ID |
N04BC09
|
||||
| Target and Pathway | |||||
| Target(s) | D(2) dopamine receptor | Target Info | Agonist | [3] | |
| KEGG Pathway | Rap1 signaling pathway | ||||
| cAMP signaling pathway | |||||
| Neuroactive ligand-receptor interaction | |||||
| Gap junction | |||||
| Dopaminergic synapse | |||||
| Parkinson's disease | |||||
| Cocaine addiction | |||||
| Alcoholism | |||||
| PANTHER Pathway | Heterotrimeric G-protein signaling pathway-Gi alpha and Gs alpha mediated pathway | ||||
| Heterotrimeric G-protein signaling pathway-Gq alpha and Go alpha mediated pathway | |||||
| Dopamine receptor mediated signaling pathway | |||||
| Nicotine pharmacodynamics pathway | |||||
| Reactome | Dopamine receptors | ||||
| G alpha (i) signalling events | |||||
| WikiPathways | Hypothetical Network for Drug Addiction | ||||
| Monoamine GPCRs | |||||
| GPCRs, Class A Rhodopsin-like | |||||
| Genes and (Common) Pathways Underlying Drug Addiction | |||||
| GPCR ligand binding | |||||
| GPCR downstream signaling | |||||
| Nicotine Activity on Dopaminergic Neurons | |||||
| References | |||||
| REF 1 | Rotigotine: a novel dopamine agonist for the transdermal treatment of Parkinson's disease. Drugs Today (Barc). 2006 Jan;42(1):21-8. | ||||
| REF 2 | 2007 FDA drug approvals: a year of flux. Nat Rev Drug Discov. 2008 Feb;7(2):107-9. | ||||
| REF 3 | Drugs used to treat Parkinson's disease, present status and future directions. CNS Neurol Disord Drug Targets. 2008 Oct;7(4):321-42. | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.